Gann H, Riemann D, Stoll S, Berger M, Müller W E
Department of Psychiatry, Central Institute of Mental Health, Mannheim, Germany.
Biol Psychiatry. 1995 Sep 1;38(5):325-9. doi: 10.1016/0006-3223(94)00368-D.
Growth hormone (GH) responses to the alpha 2-adrenoceptor agonist clonidine and to GH-releasing hormone (GHRH) were measured in 12 patients fulfilling DSM-III-R criteria for major depressive disorder and in 12 age- and sex-matched controls. GH responses to clonidine correlated significantly with the GH responses to GHRH in the depressed patients as well as in the controls. Neither the responses to clonidine nor the responses to GHRH were significantly lower in depressed patients than in controls. Similarly, somatomedin-C (Sm-C) plasma concentrations and baseline GH concentrations were not different between the two groups. The data do not suggest that blunted GH responses to clonidine and/or GHRH represent specific features of depression.
对12名符合DSM-III-R重性抑郁症标准的患者以及12名年龄和性别匹配的对照者，测量了生长激素（GH）对α2-肾上腺素能受体激动剂可乐定和生长激素释放激素（GHRH）的反应。在抑郁症患者和对照者中，GH对可乐定的反应与GH对GHRH的反应显著相关。抑郁症患者对可乐定的反应和对GHRH的反应均不比对照者显著降低。同样，两组间的胰岛素样生长因子-C（Sm-C）血浆浓度和基础GH浓度没有差异。这些数据并不表明GH对可乐定和/或GHRH反应减弱是抑郁症的特异性特征。
